ContextVision is pleased to announce that Arto Järvinen has been promoted to the company’s CTO position. Järvinen has been Director of R&D since 2011 and has been instrumental in leading the company’s operational R&D work. Järvinen has succeeded the former CTO and co-founder Martin Hedlund. Hedlund retired earlier this year but will resume in his board position for the company.
ContextVision announces first digital pathology patent granted for its unique and objective data-generation method
Master Annotation method has received patent protection in the U.S. The U.S. Patent and Trademark Office (USPTO) has granted a patent to ContextVision for this invention, titled “method and system for detecting pathological anomalies in a digital pathology image and method for annotating a tissue slide”.
ContextVision unveils latest innovation in advanced medical imaging At this year’s RSNA, ContextVision demonstrates RiventTM, taking image enhancement for ultrasound to a whole new level STOCKHOLM – Nov. 18, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, provides cutting-edge technology to support clinicians to accurately interpret medical images, […]
ContextVision – Strong Q3 with solid sales, good inflow of new customers and first product in digital pathology enters beta-testing phase
STOCKHOLM – October 24, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, has seen a strong third quarter in 2019 as new customers have been added and the first product in digital pathology has entered the beta-testing phase. Q3 sales reached 23 MSEK and total sales are growing […]
Nordnet have published an investor presentation of ContextVision. Please find the interview with CEO Fredrik Palm below (in Norwegian/Swedish) or follow this link.
ContextVision – Second quarter saw commercial release of first AI-based product, Altumira™, Digital Pathology on track and record sales
STOCKHOLM – August 15, 2019 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, continued to advance its artificial intelligence portfolio in the second quarter 2019. The company’s AI-based product Altumira™ for X-ray is now commercially available and INIFY Prostate for digital pathology will soon move to beta testing in […]
ContextVision’s Deep Learning experts will hold an oral presentation at the Medical Imaging & Deep Learning conference in London July 8–10
This paper presents an interesting and novel idea of a deep learning (DL) framework to segment potentially cancerous areas in prostate biopsies using semi-automatically generated data. The application of this paper is quite innovative and the proposed method seems to be a direct assistance to the clinical routine.
ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, reported strong sales in Q1, reaching 21.1 MSEK, 9% higher than the first quarter last year. The company reports positive feedback from user tests within digital pathology and continues to proceed with product development for this fast-growing market.
ContextVision Earns Acclaim from Frost & Sullivan for Its AI-powered INIFY™ Prostate Cancer Screening Platform
Based on its recent analysis of the European prostate cancer screening market, Frost & Sullivan recognises the Stockholm-based ContextVision AB with the 2019 European Technology Leadership Award for its INIFY™ Prostate platform.
ContextVision will have exclusive rights to the scanning cohort and access to anonymized associated clinical data - with cleared and structured histopathological descriptions, diagnosis and outcome data - for the defined patient cohorts and all commercial rights from output based on the data.The agreement gives ContextVision an opportunity to create AI-based decision support tools that will help doctors make more accurate treatment decisions. Today, many cancer patients suffer from life impairing side effects from treatments they did not need while other patients do not get treatment which is necessary.